Form 4: Odyssey Therapeutics Director Receives Stock Option Grant

Director Ourania Tatsis was granted 27,393 stock options in Odyssey Therapeutics, Inc. vesting in one year.

Summary

• Director Ourania Tatsis acquired 27,393 stock options in Odyssey Therapeutics, Inc. (ODTX).
• The options have an exercise price of $18.00 per share.
• The grant date for the transaction was May 7, 2026.
• The options are scheduled to vest in full on May 7, 2027, contingent upon continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Vesting is subject to the director's continued service, creating a dependency on personnel retention.

Future Outlook

The options vest in full on May 7, 2027, provided the director remains in service to the company.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard practice in the biotechnology sector to incentivize long-term strategic oversight and align board interests with corporate performance.

Comparison to Industry Standards

• The one-year cliff vesting schedule is consistent with standard corporate governance practices for non-employee director compensation in the life sciences industry.

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of options on May 7, 2027.

Key Dates

Keywords

Odyssey Therapeutics, ODTX, Form 4, Insider Trading, Stock Options, Director Compensation